Kleder

Lenalidomide, the active ingredient in Kleder, is an immunomodulatory imide drug (IMiD) presented as an oral dosage form for oral use. It treats multiple myeloma and myelodysplastic syndromes in adult patients.

GNH USA supplies Kleder as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The product complies with European Union regulatory standards and is distributed under strict quality‑assured conditions. It is intended for use in specialized oncology and hematology settings. GNH USA’s global logistics network ensures timely delivery to accredited healthcare facilities.

Lenalidomide is employed in hematologic malignancies and related bone‑marrow disorders.

Multiple myeloma: improves progression‑free survival and overall response rates in adult patients. Myelodysplastic syndromes with del(5q): reduces transfusion dependence and corrects cytopenias. Myelodysplastic syndromes (non‑del5q): enhances blood cell production and may delay disease progression.

Lenalidomide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools. - Rash: skin redness or itching.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly low neutrophil count increasing infection risk. - Hepatotoxicity: elevated liver enzymes or liver injury.

When prescribing Lenalidomide, several safety considerations should be observed.

Pregnancy contraindication: Category X; avoid use in pregnant women and ensure effective contraception. Thrombosis risk: assess patient history and consider prophylactic anticoagulation. Hematologic monitoring: perform regular complete blood counts to detect neutropenia or anemia. Hepatic function: evaluate liver enzymes before initiation and monitor periodically. Drug interactions: review concomitant medications for potential CYP3A4 modulators. Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Lenalidomide interacts with several drug classes; awareness of the interaction level guides clinical management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase exposure. - Thalidomide: combined teratogenic and additive toxicity. - Live vaccines: reduced efficacy and infection risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): decrease exposure. - NSAIDs: may raise renal adverse event risk. - Anticoagulants (e.g., warfarin): monitor coagulation parameters.